|
|
|
|
| LEADER |
00000cam a2200000Mu 4500 |
| 001 |
13543627 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
211225s2021 si o ||| 0 eng d |
| 005 |
20240921000232.4 |
| 035 |
|
|
|a (OCoLC)1290023355
|z (OCoLC)1289370690
|
| 035 |
|
9 |
|a (OCLCCM-CC)1290023355
|
| 040 |
|
|
|a EBLCP
|b eng
|c EBLCP
|d EBLCP
|d N$T
|d OCLCF
|
| 066 |
|
|
|c (S
|
| 019 |
|
|
|a 1289370690
|
| 020 |
|
|
|a 9814998664
|
| 020 |
|
|
|a 9789814998666
|q (electronic bk.)
|
| 050 |
|
4 |
|a R733
|
| 049 |
|
|
|a MAIN
|
| 245 |
0 |
0 |
|a Modern Cancer Therapies and Traditional Medicine :
|b an integrative approach to combat cancers.
|
| 260 |
|
|
|a Singapore :
|b Bentham Science Publishers,
|c 2021.
|
| 300 |
|
|
|a 1 online resource (352 p.)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Description based upon print version of record.
|
| 505 |
0 |
|
|a Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- Dedication -- List of Contributors -- Evolution of Cancer Therapies -- Sonali Verma1, Gresh Chander1, Deepika Bhushan Raina1, Ruchi Shah2 and Rakesh Kumar1,* -- INTRODUCTION -- TARGETED CANCER THERAPIES -- Immunotherapy -- Antibody Therapy -- Interferons and Cytokines -- Cancer Vaccine Therapy -- Nanotechnology-Based Therapies -- Photodynamic Therapy -- Hyperthermia -- Role of Gene Therapy in Cancer Treatment -- Oncogene Silencing via RNAi -- Inhibitors of Signaling Cascades -- CONCLUSION
|
| 505 |
8 |
|
|a Therapeutic Targets -- Vascular Endothelial Growth Factor Receptor Signaling (VEGF) -- Therapeutic Targets -- Toll-Like Receptors (TLRs) Pathway -- T-Cell Receptor (TCR) Pathway -- Hepatocyte Growth Factor (HGF) / Met Receptor Signaling -- c-Met as a Therapeutic Target -- Platelet-Derived Growth Factor (PDGF) Signaling -- Therapeutic Implications -- Epidermal Growth Factor Receptor (EGFR) Signaling Pathway -- Roles in Disease and Therapeutic Action -- Death Receptor (DR) Signaling -- Roles in Diseases -- TARGETED THERAPY -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST
|
| 505 |
8 |
|
|a ACKNOWLEDGEMENTS -- REFERENCES -- Biomarkers for Cancer Therapy -- Indu Sharma1, Jyotsna Sharma2, Hemender Singh2 and Varun Sharma1,* -- INTRODUCTION -- DIFFERENT BIOMARKERS IN CANCERS -- DNA as a Biomarker -- RNAs as Biomarkers -- Proteins as Biomarkers -- BIOMARKERS AND PERSONALIZED MEDICINES -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Targeted Molecular Therapies in Cancer -- Prince Anand1,2,#, Sourabh Soni1,2,# and Yogendra S. Padwad1,2,* -- INTRODUCTION -- Contour of its Mechanism: The Way Targeted Therapies Works
|
| 505 |
8 |
|
|a Hormone Therapy: Starve Cancer Cells of the Hormones It Needs To Grow -- Signal Transduction Inhibitors and Gene Expression Modulators: Stop Cancer Cells from Multiplying -- Apoptosis Inducers: Inducing Cell Death -- Angiogenesis Inhibitors: Inhibiting Stimuli that Help the Formation of New Blood Vessels in Tumors -- Immunotherapies: Aiding the Immune System of an Individual to Eliminate Cancer Cells -- LANDSCAPE OF TARGETED MOLECULAR THERAPIES: CLASSES, NOMENCLATURE, CATEGORIES, MODE OF ACTION AND CLINICAL SCENARIO
|
| 500 |
|
|
|a The Two Major Classes of Targeted Therapy: Small Molecules and Monoclonal Antibodies (mAbs/MAbs).
|
| 650 |
|
0 |
|a Cancer
|x Treatment.
|0 http://id.loc.gov/authorities/subjects/sh85019547
|
| 650 |
|
0 |
|a Cancer
|x Alternative treatment.
|0 http://id.loc.gov/authorities/subjects/sh88002328
|
| 650 |
|
0 |
|a Integrative medicine.
|0 http://id.loc.gov/authorities/subjects/sh2003001256
|
| 650 |
|
0 |
|a Evidence-based medicine.
|0 http://id.loc.gov/authorities/subjects/sh97007984
|
| 650 |
|
0 |
|a Naturopathy.
|0 http://id.loc.gov/authorities/subjects/sh85090300
|
| 650 |
|
7 |
|a Cancer
|x Alternative treatment.
|2 fast
|0 (OCoLC)fst00845320
|
| 650 |
|
7 |
|a Cancer
|x Treatment.
|2 fast
|0 (OCoLC)fst00845538
|
| 650 |
|
7 |
|a Evidence-based medicine.
|2 fast
|0 (OCoLC)fst00917247
|
| 650 |
|
7 |
|a Integrative medicine.
|2 fast
|0 (OCoLC)fst00975672
|
| 650 |
|
7 |
|a Naturopathy.
|2 fast
|0 (OCoLC)fst01034733
|
| 700 |
1 |
|
|a Singh, Shashank K.,
|e editor.
|
| 700 |
1 |
|
|a Singh, Reena,
|e editor.
|
| 700 |
1 |
|
|a Chopra, Chirag,
|e editor.
|0 http://id.loc.gov/authorities/names/n2021181113
|
| 776 |
0 |
8 |
|i Print version:
|a Singh, Shashank K.
|t Modern Cancer Therapies and Traditional Medicine:an Integrative Approach to Combat Cancers
|d Singapore : Bentham Science Publishers,c2021
|z 9789814998673
|
| 856 |
4 |
0 |
|u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=e000xna&AN=3104708
|y eBooks on EBSCOhost
|
| 880 |
8 |
|
|6 505-00/(S
|a CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Signaling Pathways in Oncotherapy -- Sonia Thapa1,2, Arem Qayum1,2, Jasvinder Singh1,2, Tenzen Yodun1,2 and Shashank K. Singh1,2,* -- INTRODUCTION -- Extracellular Messengers -- MEMBRANE RECEPTORS -- G Protein-Coupled Receptors (GPCRs) and their Signaling -- Therapeutic Targets -- Fibroblast Growth Factor (FGF) Signaling Pathway -- Therapeutic Targets -- Insulin-Like Growth Factor Receptor (IGFR) Signaling Pathway -- Therapeutic Targets -- Transforming Growth Factor-β (TGF-β) Signaling Pathway
|
| 929 |
|
|
|a oclccm
|
| 999 |
f |
f |
|i c2628ce8-b8be-4d36-879c-1a0250482678
|s f8ec1a91-f914-4e88-ab23-1dfe67ca04b4
|
| 928 |
|
|
|t Library of Congress classification
|a R733
|l Online
|c UC-FullText
|u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=e000xna&AN=3104708
|z eBooks on EBSCOhost
|g ebooks
|i 13686150
|
